Kyverna Therapeutics (KYTX) Stock Price, News & Analysis

Company Overview

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions. Kyverna’s approach centers on scalable manufacturing processes and precision cell engineering, enabling the production of off‐the‐shelf therapeutic products with defined dosing and predictable pharmacology. Collaborations with academic institutions and biotech partners support its pipeline advancement and translational research efforts.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Kyverna Therapeutics draws on a leadership team with deep expertise in cell therapy, immunology and bioprocess development. The company operates research and manufacturing facilities in the Greater Boston area and engages with regulatory authorities in North America and Europe to advance its clinical programs. Kyverna’s strategic vision is to pioneer durable, disease‐modifying treatments that address high‐unmet needs in autoimmune and inflammatory disorders.

Key Stats

• Today's Range: $8.31 to $8.55
• 50-Day Range: $7.07 to $9.91
• 52-Week Range: $3.55 to $13.67
• Volume: 524,922 shs
• Average Volume: 679,518 shs
• Market Capitalization: $517.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Moderate Buy

Kyverna Therapeutics Stock Analysis - MarketRank™

Kyverna Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 771st out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kyverna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Kyverna Therapeutics has a consensus price target of $30.00, representing about 258.4% upside from its current price of $8.37.

Amount of Analyst Coverage

Kyverna Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($2.70) to ($2.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyverna Therapeutics is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyverna Therapeutics is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kyverna Therapeutics has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.68% of the float of Kyverna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kyverna Therapeutics has a short interest ratio ("days to cover") of 13.34, which indicates bearish sentiment.

Change versus previous month

Short interest in Kyverna Therapeutics has recently increased by 3.93%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kyverna Therapeutics does not currently pay a dividend.

Dividend Growth

Kyverna Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.94

News Sentiment

Kyverna Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Kyverna Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for KYTX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

3 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.60% of the stock of Kyverna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

18.08% of the stock of Kyverna Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 8/30/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KYTX
• Previous Symbol: NASDAQ:KYTX
• CIK: 1994702
• Web: kyvernatx.com
• Phone: 510-626-8331
• Fax: N/A
• Employees: 96
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Kyverna Therapeutics: $30.00
• High Price Target: $33.00
• Low Price Target: $25.00
• Potential Upside/Downside: +258.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$161.31 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -81.92%
• Return on Assets: -63.74%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 9.06
• Quick Ratio: 9.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.85 per share
• Price / Book: 2.17

Miscellaneous

• Outstanding Shares: 61,840,000
• Free Float: 50,959,000
• Market Cap: $517.60 million
• Optionable: Optionable
• Beta: 1.93